Editorial Board ::: Current Drug Discovery Technologies

ISSN: 1875-6220 (Online)
ISSN: 1570-1638 (Print)


Volume 14, 4 Issues, 2017


Download PDF Flyer




Current Drug Discovery Technologies

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Vladimir P. Torchilin
Department of Pharmaceutical Science Center
for Pharmaceutical Biotechnology and Nanomedicine
Northeastern University
Boston, MA 02115
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Editor-in-Chief:

Vladimir P. Torchilin (Biography
Vladimir P. Torchilin

Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 44,000 citations of his papers with H-index of 96. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.

)

Department of Pharmaceutical Science Center
for Pharmaceutical Biotechnology and Nanomedicine
Northeastern University
Boston, MA 02115
USA



Regional Editors:

Grzegorz Bazylak (Biography
Grzegorz Bazylak

Prof. Bazylak received Ph.D. in Food Chemistry from the Technical University, Lodz, Poland and D.Sc. (habilitation) in Pharmacy from the Medical University, Gdansk, Poland. He served as post-doc in the Medical University of Lodz (Poland) and the University of Antwerp (Belgium). He is working from 2004 as the Associate Professor and Head of Pharmaco-Bromatology and Molecular Nutrition at the Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University in Bydgoszcz, Poland. He has published more than 150 scientific publications, edited the 12 special topic issues of international scholary journals and is now engaged in the jury of the 20th edition of the Annual Pharmacy Professor’s Award in Poland.

)

Nicolaus Copernicus University
Bydgoszcz
Poland

Eduardo A. Castro
INIFTA, Theoretical Chemistry Division
La Plata, Buenos Aires
Argentina

Detlev Boison (Biography
Detlev Boison

Having a passion for translational research I seek to translate fundamental mechanisms of biochemistry and energy homeostasis into novel therapeutic approaches for the treatment of neurological and psychiatric conditions. A major research effort is the development of adenosine augmentation therapies for the treatment of epilepsy. I graduated at the University of Cologne, Germany, in 1994 with a PhD in Biochemistry. In 1995 I started my independent research career at the University and Federal Institute of Technology in Zurich where I received the venia legendi in Cellular Pharmacology in 2005 for my work on cell-based adenosine augmentation therapies for epilepsy. That same year I joined Legacy Health in Portland, Oregon, where I am currently Chair and Director of the Robert Stone Dow Neurobiology Laboratories and Director of Basic and Translational Research of the Legacy Research Institute. In addition, I hold faculty appointments at Oregon Health and Science University and at Washington State University.

)

RS Dow Neurobiology Laboratories
Portland
OR
USA

Yiyun Cheng (Biography
Yiyun Cheng

Dr. Cheng obtained a doctorate (PhD) in Structural Biology from the University of Science and Technology of China. Currently Dr. Cheng is a Professor in the School of Life Sciences, East China Normal Universty. He has published more than 100 papers in journals such as Nature Materials, Nature Communications, J. Am. Chem. Soc. and Angew. Chem. Int. Ed. Dr. Cheng is currently the Editorial Board Member of Letters in Drug Design & Discovery, and the guest editor of Topics in Current Chemistry. His research focused on drug and gene delivery systems.

)

East China Normal University
Shanghai
China

Martin Braddock (Biography
Martin Braddock

Martin Braddock is a professional scientist and project manager working in the field of drug discovery and development with 32 years experience of working in academic institutes Universities of Dundee and Oxford) and large corporate organisations. He holds a BSc in Biochemistry and a PhD in Radiation Biology (both from the University of Salford) and is a former Royal Society University Research Fellow at the University of Oxford. His current role is Global Products Manager and Global Alliance Manager for Tralokinumab, an anti-IL-13 monoclonal antibody for the treatment of patients with severe asthma presently undergoing phase III clinical trials.

)

AstraZeneca Research and Development
Leicestershire
UK


Section Editor:

(Environmental Endocrinology)
M. Ishido (Biography
M. Ishido

Evolution of molecular biology directs my research carrier to investigate the mechanism of homeostasis. Emission of chemicals to environment is global. The most important fact from health studies of environmental chemicals is that impacts on health might inherit to the next generation, through epigenetics. Epigenetics provides molecular mechanisms for the environment to directly alter phenotypic variation and its subsequent inheritance. Epigenetics should be considered as environmental pressure for the origins of genotypic variation and rapid evolutionary phenomenon as well as classical genomics, which would open the way to be explained. Epigenetic modification would increase the frequency of potentially inheritable mutations. Thus, to extend the research field that I have chosen so far will be fruitful from standing on the point of Evolutionary Developmental Biology, integrating Environmental Sciences and Life Sciences.

)

National Institute for Environmental Studies
Tsukuba
Japan


Editorial Board Members:

B.B. Aggarwal
University of Texas, MD Anderson Cancer Center
Houston, TX
USA

A.M. Aronov (Biography
A.M. Aronov

Alex Aronov received his PhD in bioorganic chemistry from the University of Washington in 1998. He completed his postdoctoral training at UCSF, working on structure-based design and synthesis of novel anti-parasitics, and holds an MBA from MIT Sloan. He started his industrial career in molecular modeling at Vertex Pharmaceuticals in Cambridge, MA. From 2007 to 2012, he led a cross-functional team to deliver a novel immuno-oncology therapy BVD-723. He is currently Director and Head, Early Discovery Modeling & Informatics at Vertex, with responsibility for global Modeling & Informatics support of Vertex’s early discovery efforts. He is an author of 30 peer-reviewed manuscripts, and is an inventor on over 40 international patent applications

)

Vertex Pharmaceuticals, Inc
Cambridge, MA
USA

M.B. Brown
University of Hertfordshire
Herts
UK

R. Cortesi (Biography
R. Cortesi

Dr. Rita Cortesi obtained her doctorate (Ph.D.) in Pharmaceutical Sciences from the University of Ferrara, Italy. She attended a HMC Post-doc fellowship at Pharmaceutical Sciences Department of Nottingham University (U.K.).

Currently Dr. Cortesi is an Associate Professor at the Department of Life Sciences and Biotechnology of Ferrara University. She has published more than 120 scientific publications considering papers on international journal, book’s chapters and patents. Dr. Cortesi currently belongs to the Editorial Board of this journal (Current Drug Discovery Technologies, CDDT), published by Bentham Science Publishers.

)

Ferrara University
Ferrara
Italy

M.M. De Villiers (Biography
M.M. De Villiers

Melgardt de Villiers is Professor and Associate Dean at the School of Pharmacy - University of Wisconsin. His research focuses on developing innovative nano and micro particulate drug delivery systems. He is the author of 150 peer reviewed publications and book chapters and has presented his research at meetings more than 200 times. He has supervised 17 PhD and 21 MS students. In 2005 he was the Outstanding Professor in the College of Health Sciences at the University of Louisiana at Monroe and in 2012 he was elected as a fellow of the American Association of Pharmaceutical Scientists (AAPS).

)

University of Wisconsin
Madison, WI
USA

I. Doytchinova
Medical University of Sofia
Sofia
Bulgaria

Y. Fang (Biography
Y. Fang

Dr. Ye Fang is the Research Director/Fellow of the Biochemical Technologies in the Science & Technology Division at Corning Incorporated in New York (NY, USA). He received his BSc in Chemistry from the Hubei University, MSc in Physical Chemistry from the Wuhan University, and Ph.D in Physical Chemistry from the Institute of Chemistry, Chinese Academy of Sciences, all in China. Following postdoctoral research at the University of Vermont from 1995 to 1996 and at the Johns Hopkins University School of Medicine from 1996 to 2000, he joined Corning Incorporated. Over the last 24 years, he has focused his scientific interests on the biophysical aspects of bio-macromolecules and cells, as well as the development of innovative biotechnologies for cell biology, drug discovery, and bioprocess. He has published 2 books, 24 book chapters, and more than 120 journal articles. He holds 28 US granted patents and 70 patent applications. His current research interests are Biosensors, Biophysics, Bioprocess, Chemical Biology, Drug Discovery, and Pharmacology.

)

Corning Inc
Corning, NY
USA

D.R. Flower (Biography
D.R. Flower

Darren Flower, a truly interdisciplinary scientist, an innovative specialist in bioinformatics, computational chemistry, and cheminformatics, with unique and unparalleled experience of the pre-clinical research environment in both academia and the pharmaceutical industry with interests in drug and vaccine design. He is currently a Reader in Pharmacy at Aston University UK. Dr Flower is a Fellow of the Royal Society of Chemistry (RSC) and a Fellow of the Higher Education Academy. He is author of over 165 peer-reviewed papers (3 citation classics (400+ citations) and 31 mini-classics (100+ citations)), with a GS H-index of 51. Dr Flower is the Author of the monograph: "Bioinformatics for Vaccinology" and has edited 6 other books.

)

Aston University
Birmingham
UK

J.C. Glorioso
University of Pittsburgh
Pittsburgh, PA
USA

C.P. Hart (Biography
C.P. Hart

Charles Hart joined Threshold Pharmaceuticals in 2004 and is currently Senior Vice President for Discovery Research. He is responsible for both in vitro and in vivo preclinical translational studies. Prior to joining Threshold he held positions at Galileo Pharmaceuticals, Signature Bioscience, and the Affymax Research Institute. Charles received his A.B. in cell biology from the University of California at Berkeley in 1977, an M.S. in developmental biology from Stanford University in 1980, a Ph.D. in molecular biology and genetics from Yale University in 1987, and completed a postdoctoral fellowship at the University of Strasbourg, France.

)

Threshold Pharmaceuticals
Redwood City, CA
USA

K. Houk
University of California
Los Angeles, CA
USA

K. Islam
Arpida Ltd
Muenchenstein
Switzerland

J. Kardos (Biography
J. Kardos

Julianna Kardos Ph.D. (1973), D.Sc. (1991) studied chemistry at the Eötvös Loránd University, Budapest, Hungary in 1964-1969. She was associate professor in pharmacology (1986-1987: Georgetown University, Washington DC, USA), research specialist in biochemistry (1988, 1989: University of Missouri-Columbia, St.Louis, MO, USA) and research specialist in pharmacy (1993, 1995: Royal Danish School of Pharmacy), head of department (1995-2011: Chemical Research Center, Hungarian Academy of Sciences, HAS) and director of the Institute of Molecular Pharmacology (2012-2013). She is currently professor emeritus at the Research Centre for Natural Sciences, HAS, Budapest. She is the recipient of the Award of HAS, Budapest, Hungary (2006).

)

Hungarian Academy of Sciences
Budapest
Hungary

S. Klussmann
Noxxon Pharma AG
Berlin
Germany

M.S. Lajiness ()
Eli Lilly and Company
Indianapolis, IN
USA

C. Lipinski (Biography
C. Lipinski

Dr. Christopher Lipinski is Scientific Advisor to Melior Discovery and is the author of the “rule of five” a filter for acceptable drug oral absorption. Chris is a member of the “Medicinal Chemistry Hall of Fame”. In 2006 he received an honorary law degree from the University of Dundee and the SBS Achievement Award. In 2005 he won the Hershberg Award for Important Discoveries in Medicinally Active Substances and in 2004 won the ACS Division of Medicinal Chemistry Award. An adjunct faculty member at the University of Massachusetts Amherst, Chris has over 275 publications and invited presentations and 19 issued US patents.

)

Melior Discovery
Waterford, CT
USA

C.R. Martin
University of Florida
Gainesville, FL
USA

L.M. Mayr (Biography
L.M. Mayr

Lorenz is working as Vice President, Reagents & Assay Development with global responsibility for generation of biological reagents and assay development activities at AstraZeneca. This includes generation of proteins and cell lines for hit finding, hit-to-lead and lead optimisation activities including structure & biophysics activities across all therapeutic research areas, the generation of tool antibodies, transgenic animals, stem cells and primary cells as tools for target validation studies and lead optimisation programmes. His department in the UK and Sweden is responsible for assay development activities for biochemical, cell-based and phenotypic assays for all therapeutic areas at AstraZeneca. Current research interests of the RAD Department are in the areas of precise-genome editing (PGE), transcriptomics, secretomics, high-content biology, novel antibody scaffolds and affinity reagents, next-generation sequencing (NGS) and the use of these technologies in complex 3D cellular models/organoids for target validation and lead optimisation.

)

AstraZeneca Pharmaceuticals Ltd.
Cheshire
USA

S.M. Moghimi (Biography
S.M. Moghimi

Moein Moghimi joined Durham University in 2016 where he serves as Professor and Chair in Pharmaceutics at the School of Medicine, Pharmacy and Health. He is also a Full Affiliate Member/Professor at the Department of Translational Imaging, Houston Methodist Research Institute, Houston Methodist Hospital Systems (Houston, Texas, USA) and Adjoint Professor at the Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver Medical Center (USA). In 2015, Moein was a Visiting Professor at Università Degli Studi Di Padova, Italy. Between 2008 and March 2016, he was based at the University of Copenhagen (Denmark) serving as Professor of Nanomedicine at the Department of Pharmacy, Professor of Pharmaceutical Nanotechology at the NanoScience Centre, and the Founder and Director of the multi-million Euro Centre for Pharmaceutical Nanotechnology and Nanotoxiocology (the first interdisciplinary nanomedicine research centre in Denmark). Between 2008 and 2010, he further served as the Honorary Professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University (China). Professor Moghimi’s research activities are focused on pharmaceutical nanoscience, nanomedicine and nanosafety.

)

School of Medicine, Pharmacy and Health
Durham University
Queen's Campus
UK

D.J. Muller
University of Technology Dresden
Dresden
Germany

H. Onishi
Hoshi University
Tokyo
Japan

R.T. Peterson
Massachusetts General Hospital
Charlestown, MA
USA

I.N. Rich
HemoGenix, Inc
Colorado Springs, CO
USA

M. Ruvo (Biography
M. Ruvo

Dr. Ruvo graduated in Chemistry at the University of Naples in 1991. He spent the first 10 years of his career as industrial researcher (Tecnogen, Italy), working as head of the protein and peptide laboratory and contributing at the development of several bioactive peptides. In 2002, he joined the Institute of Biostructures and Bioimaging of the National Research Council (IBB-CNR) in Naples, working as senior scientist and leading several projects focused on the development of new bioactive peptides and monoclonal antibodies against targets with a role in cancers development. Among the others, he has developed peptides modulating the activity of PlGF, Cripto, and Gadd45β and mAbs against Nodal, the E2 protein of HCV and Cripto. He is also the scientific founder of Kesios Therapeutics Ltd (London). He is author of about 100 papers and inventor of >10 patents.

)

Istituto di Biostrutture e Bioimmagini
Napoli
Italy

V. Shanmugasundaram
Pfizer PharmaTherapeutics Research & Development
Groton, CT
USA

C.P. Sosa
University of Minnesota
Minneapolis, MN
USA

K. Sugahara (Biography
K. Sugahara

Dr. Sugahara obtained master’s degree (MS) and Ph.D. in Biological Chemistry from the Faculty of Pharmaceutical Sciences, Kyoto University, Japan. He awarded Honorary Doctor of Medicine from Uppsala University, Sweden in 2002, and Human Frontier Science Award (Strasbourg) in 2000 and 2010. He has published over 220 peer reviewed original scientific publications and over 20 review articles, and specializes in glycobiology of sulfated polysaccharides and extracellular matrix proteins. Currently he is Emeritus Professor, Hokkaido University, Sapporo, Japan, and Research Fellow at Department of Pathobiohemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.

)

Hokkaido University Graduate School of Life Science
Hokkaido
Japan

I.V. Tetko (Biography
I.V. Tetko

Dr. Igor V. Tetko obtained his MSc degree (with honor) from the Moscow Institute of Physics and Technology (USSR), PhD from the Ukrainian Academy of Sciences and Habilitation in Chemoinformatics from the University of Strasbourg. He is Chemoinformatics group leader at the Helmholtz Zentrum München, Germany where he coordinates Horizon2020 Marie Skłodowska-Curie Innovative Training Network (ITN) “Big Data in Chemistry”. Dr. Tetko is also CEO of BIGCHEM GmbH, which develops and licenses software technologies for big data analysis in chemistry and life sciences. Dr. Tetko is on the list of The Most Cited Researchers in Computer Sci. & Eng.

)

Institute for Bioinformatics
Neuherberg
Germany

G. Trainor
Bristol-Myers Squibb Pharmaceutical
Delaware, NJ
USA

M.A. Walker
Bristol-Myers Squibb R&D
Wallingford, CT
USA

C. William (Biography
C. William

Dr William Cho is a Biomedical Scientist in Queen Elizabeth Hospital. His main research interests have been focusing on cancer studies utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), Guest Professor of a number of Universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr Cho has published over 200 peer-reviewed papers (Lancet Oncology, Clinical Cancer Research, Clinical Chemistry, Annual Oncology, etc) covering cancer biomarkers, proteomics, microRNAs, Chinese medicine and plenty of books including "MicroRNAs in cancer translational research", "An omics perspective on cancer research", "Supportive cancer care with Chinese medicine", etc.

)

Queen Elizabeth Hospital
Yau Tsim Mong
Hong Kong

A.K. Yudin
University of Toronto
Toronto, Ontario
Canada

J. Zhou (Biography
J. Zhou

Dr. Zhou is a tenured Professor in the Chemical Biology Program at University of Texas Medical Branch (UTMB). He was educated and trained from Nankai University, University of Virginia, and Georgetown University Medical Center, respectively. He has over 20 years of research experience in drug discovery and development including 7 years of industrial experience in pharmaceuticals. His research interest is developing novel small molecules as valuable chemical probes and potential therapeutics for central nervous system disorders, cancer/inflammation, and infectious diseases. He has published more than 100 peer-reviewed journal papers, 6 book chapters, and 15 patents.

)

University of Texas
Galveston, TX
USA

A.K. Agrawal (Biography
A.K. Agrawal

Dr Ajay K Agrawal has been in the board of directors of companies in UK, Europe and USA and in the editorial board of number of journals, published by Bentham Science Publishers.

Previously, he was a founder of polyMASC Pharmaceuticals plc, London, the first UK biotech company from a university that was directly listed on London stock exchange, raising approximately $40 million in 1995, and the Managing Director of the worldwide organization of collaborations in the pharmaceutical industry, London, and special advisor on healthcare for commonwealth Business council, London.

)

ImmuPharma plc
London
UK

Igor Baskin (Biography
Igor Baskin

Igor Baskin received his PhD (kandidat nauk) in organic chemistry (1990) and habilitation (doctor nauk) in mathematical chemistry (2010) from Lomonosov Moscow State University, Russia. After holding several positions at the Semenov Institute of Chemical Physics and Zelinsky Institute of Organic Chemistry of the Russian Academy of Sciences, Moscow, he joined in 2001 Lomonosov Moscow State University, where since 2005 he holds the position of a Leading Scientist. He is regularly engaged as Visiting Scientist and Invited Professor at the University of Strasbourg, France. He is a co-author of 4 textbooks and more than 160 peer-reviewed articles and book chapters related to chemoinformatics, artificial neural networks, medicinal chemistry, as well as molecular modeling of biological receptors and supramolecular systems. Igor Baskin is a member of the International Academy of Mathematical Chemistry since 2009. His current work focuses on the use of machine learning and artificial intelligence in chemoinformatics, drug discovery and materials science.

)

Lomonosov Moscow State University
Moscow
Russia

K.K. Chan
The Ohio State University
Ohio, OH
USA

M. Cristofanilli
The University of Texas
Houston, TX
USA

A. Degterev (Biography
A. Degterev

Dr. Degterev is an Associate Professor at the Department of Developmental, Molecular and Chemical Biology at Tufts University. His work focuses on the analysis of the mechanisms and development of the small molecule modulators of cell death processes that contribute to human pathologies. Dr. Degterev pursues multidisciplinary studies combining cell and chemical biology, and animal pharmacology. Dr. Alexei Degterev earned M.S. in Chemistry from Moscow State University, Russia and Ph.D. in Biochemistry from Boston University School of Medicine, MA. Upon graduation, he joined the laboratory of Dr. Junying Yuan in the Department of Biology of Harvard Medical School as a post-doctoral fellow and, subsequently, as Instructor in Cell Biology. Since November 2005, Dr. Degterev is an Assistant Professor of Biochemistry at Tufts University. Dr. Degterev is a recipient of the Mentored Career Development Award from the National Institute on Aging, Alzheimer’s Research Pilot Award from the American Health Assistance Foundation and Smith Family Award for Excellence in Biomedical Research from the Massachusetts Medical Foundation. Dr. Degterev is the author of multiple patents and more than 60 scientific publications.

)

Tufts University School of Medicine
Boston, MA
USA

T.L. Dunckley
Translational Genomics Research Institute
Phoenix, AZ
USA

M. Feher
D. E. Shaw Research
New York, NY
USA

A. Fura
Bristol-Myers Squibb R&D
Princeton, NJ
USA

B. Gold
National Cancer Institute
Frederick, MD
USA

A. Hillisch
Bayer HealthCare AG
Wuppertal
Germany

J. Huard
Department of Orthopaedic Surgery
University of Texas Health Science Center at Houston
Houston
United States

S. Jana (Biography
S. Jana

Dr. Snehasis Jana has more than 15 years of new drug discovery and development research experience in various Indian pharmaceutical industries. He holds a basic degree in Pharmaceutical Sciences, a PhD in Molecular mechanisms of Drug Resistance Mechanisms (Molecular Pharmacology & Biotechnology) from Dept. of Biochemical Engg. & Biotechnology, IIT-Delhi, India and has extensive drug discovery & developmental research experience in various therapeutic targets at Ranbaxy, BMS-Biocon Research Center, Sai Life Science & Laila Nutraceuticals. He is an expert for establishing strategic directions for preclinical/clinical nutra/pharmaceuticals discovery research focused on Anticancer, Chemopreventive agents, Probiotics/prebiotics, hepatoprotective, anti-infective, anti-inflammatory, arthritis, Cardiovascular, anti-aging, obesity, diabetes, Cognition & Memory, and Overall health etc. Dr. Jana's publication record exceeds 45 research articles and reviews.

)

Trivedi Science Research Laboratory
Madhya Pradesh
India

K. Kariko
University of Pennsylvania School of Medicine
Philadelphia, PA
USA

M. Komada (Biography
M. Komada

Dr. Komada obtained a Ph.D. degree in Pharmaceutical Science from the University of Tokyo. Dr. Komada currently studies cell biology, focusing on how cell proliferation is regulated by ubiquitination-dependent growth factor receptor downregulation and how its impairment leads to human tumors. He recently discovered that somatic gain-of-function mutations in a deubiquitinating enzyme USP8 cause pituitary tumor which results in Cushing’s disease. This discovery opened a path for the medical treatment of the disease.

)

Tokyo institute of Technology
Yokohama
Japan

J.M. Lehn
Nobel Laureate Institut Le Bel
Cedex
France

S.A. Lipton
University of California
La Jolla, CA
USA

L.C. Mattheakis (Biography
L.C. Mattheakis

Dr. Mattheakis is currently Vice President of Biology at Protagonist Therapeutics. His nearly 25 years of experience in biotech R&D includes developing novel technologies for drug screening and leading preclinical programs in oncology and immune disorders. He is the author of numerous publications and inventor on key patents. Dr. Mattheakis received a Ph.D. in Biochemistry from the University of Wisconsin-Madison, and trained as a post-doctoral research fellow in the Department of Microbiology and Molecular Genetics at Harvard Medical School. He is a member of Faculty of 1000 in Chemical Biology, and serves as an editor for the Journal of Biomolecular Screening (SLAS Discovery).

)

Protagonist Therapeutics Inc.
Newark, CA
USA

L.K. Minor
Johnson & Johnson Pharmaceutical R&D
Spring House, PA
USA

M. Moloney (Biography
M. Moloney

Professor Mark Moloney completed his undergraduate and graduate studies at the University of Sydney. In 1985, he moved to the University of Oxford as a postdoctoral fellow working with Professor Sir Jack Baldwin, and was appointed to a faculty position in the Department of Chemistry in 1990, where he has remained ever since. His interests include organic and medicinal chemistry; surface modification of polymers; and antibacterial drug discovery.

)

University of Oxford
Oxford
UK

J.P. O'Bryan
University of Illinois College of Medicine
Chicago, IL
USA

E. Paleolog
Imperial College
London
UK

G. Poda (Biography
G. Poda

Dr. Gennady Poda is Principal Research Scientist and Manager, Computational Chemistry and Chemoinformatics at the Ontario Institute for Cancer Research and Assistant Professor (status only) at the Leslie Dan Faculty of Pharmacy, University of Toronto, Canada. He obtained a Master of Science degree in Molecular and Chemical Physics at the renowned Moscow Institute of Physics and Technology (MIPT) and a PhD in Bioorganic Chemistry from the Institute for Bioorganic and Petrochemistry, National Academy of Sciences in Kyiv, Ukraine. During his prominent work at Pharmacia & Upjohn, Pfizer and now OICR he demonstrated excellence in computer-aided drug design covering all aspects of modern computational drug discovery: structure-, ligand- and fragment-based drug discovery, chemoinformatics, medicinal chemistry, data mining and analysis, physical and ADMET property prediction, methods development and programming. He is a co-author of 57 publications, 3 book chapters and 7 patents.

)

Ontario Institute for Cancer Research
Toronto, ON
Canada

D.D. Root (Biography
D.D. Root

Dr. Root earned a PhD from the Molecular Biology Institute at the University of California, Los Angeles. Dr. Root currently designs and synthesizes small molecule modulators of muscle force generation based on structural and functional studies of protein interactions using spectroscopic and single molecule assays, several of which were developed in his laboratory. In addition, Dr. Root has directed courses in Biochemistry at the University of North Texas for 20 years.

)

University of North Texas
Denton, TX
USA

D.K. Sarker (Biography
D.K. Sarker

Dipak Sarker is an Associate Professor of Pharmaceutics. He graduated with a PhD in physics in 1995, and is a nanotechnologist and material scientist working in the fields of industrial product science and medical devices and drug delivery. He has a number of doctoral students and postdoctoral scientists in his interfacial nanoscience group and links with other institutions and industrial organisations.

)

University of Brighton
Brighton
UK

K.B. Sharpless
The Scripps Research Institute (TSRI)
La Jolla, CA
USA

L. Stewart
deCODE biostructures Inc
Bainbridge Island, WA
USA

D.R. Taft (Biography
D.R. Taft

Dr. Taft is a Professor of Pharmaceutics and former Dean of the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University. He received his B.S. degree in pharmacy from the University of Rhode Island (1987) and his Ph.D. from the University of Connecticut (1993). Following completion of a one-year fellowship at the University of North Carolina School of Pharmacy, Dr. Taft joined the faculty at Long Island University. His primary area of interest is pharmacokinetics, and his research involves a combination of in vitro, in vivo and in silico techniques.

)

Long Island University
Brooklyn, NY
USA

A.A. Toropov (Biography
A.A. Toropov

Andrey A. Toropov (PhD) has been working in Istituto di Ricerche Farmacologiche Mario Milano, Italy with Dr. Benfenati’s research group. The optimal (flexible) descriptors are his main scientific interest. He is developer of recent version of the optimal descriptors named as collectors of eclectic data for a QSPR/QSAR predictions. This paradigm is especially appropriate for the cases of complex molecular systems such as nanomaterials and proteins. He had done contribution for the development of the CORAL freeware (http://www.insilico.eu/coral). He had published of about 220 papers in international journals on the QSPR/QSAR analysis: physicochemical properties, toxicity, cancirogenicity, anticancer agents, anti-HIV-1 agents, QSPR/QSAR analysis for nanomaterials. He was participant of the following EC projects: DEMETRA, CHEMPREDICT, PROSIL, ORCHESTRA, ANTARES, OSIRIS, NanoBRIDGES, PreNanoTox, NanoPUZZLES etc. He is participant in work of Editorial Boards of scientific journals (as a reviewer). He has been visiting scientist in Jackson State University (USA, Mississippi), in 2006-2007.

)

IRCCS-Istituto di Ricerche Farmacologiche Mario Negri
Milano
Italy

S.M. Turner
KineMed, Inc
Emeryville, CA
USA

P.A. Wender (Biography
P.A. Wender

Paul Wender received his PhD from Yale University, was an NIH Fellow at Columbia University, served on the faculty at Harvard University and is currently the Bergstrom Professor of Chemistry and Professor of Chemical and Systems Biology at Stanford University. He serves on several internal and external advisory board and has founded various companies based on his research. His work is described in >300 publications and >20 issued or pending patents. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Association of Arts and Sciences, and the Royal Spanish Academy of Sciences. His work has been recognized with numerous awards, including more recently the 2015 Stanford Office of Technology Licensing Innovator Award, 2015 Israel Chemical Society Cohen Award for Excellence in Medicinal Chemistry, 2015 ACS Cope Award, and the 2016 Research Award of the German Bioactives and Biotechnology Leibniz Alliance.

)

Stanford University
Stanford, CA
USA

M.S. Wolfe (Biography
M.S. Wolfe

Michael S. Wolfe is the Matthias P. Mertes Professor of Medicinal Chemistry at the University of Kansas. He received his B.S. in chemistry from the Philadelphia College of Pharmacy and Science and Ph.D. in medicinal chemistry from the University of Kansas. After postdoctoral stints at the University of Kansas and the NIH, he joined the faculty of the University of Tennessee in Memphis in 1994. In 1999, he moved to Harvard Medical School and Brigham and Women’s Hospital, becoming Professor of Neurology in 2008. Awards for his work include the MetLife Award for Biomedical Research (2008) and the Potamkin Prize from the American Academy of Neurology (2009).

)

Harvard Medical School
Boston, MA
USA

Y. Zhang
Johns Hopkins University
Baltimore, MD
USA

A. Ahad (Biography
A. Ahad

Dr. Abdul Ahad is an Assistant Professor at Department of Pharmaceutics, College of Pharmacy, King Saud University Riyadh, Saudi Arabia. Dr. Ahad did his Master and Doctorate in Pharmaceutical Sciences from Department of Pharmaceutics, Jamia Hamdard, New Delhi, India. He has published various high quality research and review articles in several peer-reviewed journals of international repute. He is on Editorial Board of several Pharmaceutical journals and reviewer of many peer-reviewed journals. His current interest lies in Nanotechnology products for dermal/transdermal drug delivery and lipid based formulations.

)

King Saud University
Riyadh
Saudi Arabia

C.R. Bramham (Biography
C.R. Bramham

Dr. Bramham is head of the Neuroscience Research Group and partner in KG Jebsen Centre for Neuropsychiatric Disorders at the University of Bergen, Norway. Research in Dr. Bramham’s lab aims to elucidate the cell biological and molecular mechanisms that control synaptic plasticity in the brain, and the dysregulation of these mechanisms in cognitive disorders. Dr. Bramham has published more than 100 research papers and book chapters.

)

University of Bergen
Bergen
Norway

J.P.F. Chin-Dusting
Baker Heart Research Institute
Melbourne
Australia

J.-V. De Julian Ortiz
Polytechnic University of Valencia
Valencia
Spain

X. Deng (Biography
X. Deng

Dr. Deng is a faculty member engaged in cancer research and has held the appointment of associate professor in the Department of Radiation Oncology at Emory University School of Medicine. Dr. Deng completed his postdoctoral training at the University of Texas Medical Branch. Major research interests are to develop novel small molecule anti-cancer agents and new therapeutic strategies for cancer therapy by targeting apoptosis and DNA repair signaling pathways. He has published more than 87 scientific publications and is a named inventor of 3 issued U.S patents.

)

Emory University School of Medicine
Atlanta, GA
USA

E. Estrada (Biography
E. Estrada

Professor Estrada is the 1964 Chair of Mathematics and Chair in Complexity Sciences at the University of Strathclyde, Glasgow, U.K. He is also the President of the International Academy of Mathematical Chemistry and a Member of the Academia Europaea. He obtained his PhD in Mathematical Chemistry at the UCLV in Cuba. His research interests are on the mathematical analysis of complex networked systems as well as in mathematical chemistry and molecular design. He is well-known for the development of the TOPS_MODE approach to drug design, protein structure analysis and for the analysis of biological networks.

)

University of Strathclyde
Scotland
UK

A.K Ferreira (Biography
A.K Ferreira

Adilson Kleber Ferreira is presently the principal investigator at Biomedical Science Institute of Department of Immunology. He accomplished his Ph.D. research in the area of developments of new anticancer drugs at the Faculty of Medicine of the University of Sao Paulo in Brazil. Ferreira also did your Ph.D. in Oncology at Frank`s Laboratory at the University of Groningen Netherlands, studying the molecular effects of new drugs candidate against non-small cell lung cancer. He also completed his training with a one-year post-doctoral fellowship in the University Medical Center Groningen, Netherlands - Research Institute for Drug Exploration of Department of Oncology. He also did postdoctoral research at Department of Immunology, and it was aimed at development and validation of new anticancer compound to lung cancer treatment.

)

University of Sao Paulo
São Paulo
Brazil

Z.-G. Gao
National Institutes of Health
Bethesda, MD
USA

J.A. Grosso
Bristol-Myers Squibb R&D
Princeton, NJ
USA

A.G. Horti (Biography
A.G. Horti

Andrew G. Horti an Associate Professor in the Department of Radiology, Division of Nuclear Medicine and Molecular Imaging at the Johns Hopkins University School of Medicine. He has over 25 years of experience in medicinal radiochemistry. He holds a PhD in organic synthesis and physical chemistry from Leningrad Institute of Technology. Notably, Dr. Horti has authored more than 100 manuscripts, patents, and book chapters. His current research projects focus on the discovery of short-lived radiotracers, in particular, radioligands for PET imaging of cerebral receptors and enzymes.

)

Johns Hopkins University
Baltimore, MD
USA

A.C. Hunter
University of Manchester
Manchester
UK

J.W. Janetka
Washington University School of Medicine
Saint Louis, MO
USA

T. Kenakin (Biography
T. Kenakin

Beginning his career as a synthetic chemist, Terry Kenakin received a Ph.D. in Pharmacology at the University of Alberta, Edmonton Canada. After a post-doctoral Fellowship at University College London, U.K., he joined Burroughs-Wellcome as an associate Scientist. From there he continued working in drug discovery at Glaxo Inc.,GlaxoWellcome and finally GlaxoSmithKline. Leaving his position as a Director at GlaxoSmithKline Research and Development laboratories at Research Triangle Park, N.C. USA, Dr. Kenakin is now a professor in the Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill. Currently he is engaged in studies aimed at the optimal design of drug activity assays systems, the discovery and testing of allosteric molecules for therapeutic application and the quantitative modeling of drug effects. In addition, he is Director of the Pharmacology curriculum at the UNC School of Medicine. He is a member of numerous editorial boards as well as Editor in Chief of the Journal of Receptors and Signal Transduction and Co-editor in Chief of Current Opinion in Pharmacology. He has authored numerous articles and has written 10 books on Pharmacology.

)

University of North Carolina School of Medicine
Chapel Hill, NC
USA

W.A. Korfmacher
Schering-Plough Research Institute
Kenilworth, NJ
USA

J.-P. Leonetti
Centre de Pharmacologie et Biotechnologie pour la Sante
Montpeillier
France

E. Lolis
Yale University
New Haven, CT
USA

N. Maulik
University of Connecticut School of Medicine
Farmington, CT
USA

L. Mitscher
University of Kansas
Lawrence, KS
USA

K. Mueller
Hoffman-La Roche Ltd
Basel
Switzerland

T. Ochiya (Biography
T. Ochiya

Dr. Takahiro Ochiya is a Chief of Division of Molecular and Cellular Medicine at the National Cancer Center Research Institute, Tokyo. Dr. Ochiya carried a councilor of Japanese Cancer Association. After he got Ph.D. in 1988 in Osaka University and then went to do a post-doc at La Jolla Cancer Research (SF Burnham Institute for Medical Research), CA, USA. Dr. Ochiya’s lab focuses the development of novel animal models, methods, and strategies to study cancer development and metastasis. Especially, current focuses are siRNA- and microRNA-based therapy and exosome-mediated tumor metastasis. Dr. Ochiya has authored more than 280 peer-reviewed publications including 40 review articles, holds 26 Japan and 8 U.S. & Europe patents, and contributed to several books on stem cells, Extracellular vesicles, and RNAi medicine.

)

National Cancer Center Research Institute
Tokyo
Japan

K.H. Pearce
GlaxoSmithKline
GlaxoSmithKline, NC
USA

Y.G. Pommier (Biography
Y.G. Pommier

Yves Pommier is the Chief of the Developmental Therapeutics Branch, NCI. He obtained his M.D. and Ph.D. from the University of Paris, and has studied DNA topoisomerases and the pharmacology of their inhibitors for the past 30 years. Three of his topoisomerase I inhibitors are in clinical trials. Dr. Pommier also discovered the first HIV-1 integrase inhibitors and the mechanism of action of poly(ADPribose) polymerase inhibitors by trapping PARP-DNA complexes. He pioneered the concept of drugs acting as interfacial inhibitors.

)

National Institutes of Health
Bethesda, MD
USA

R. Roy
Universite du Quebec a Montreal
Montreal, QC
USA

J. Schlessinger
Yale University
Yale University, CT
USA

P.J. Sinko
Rutgers University
Piscataway, NJ
USA

G. Subramanian
Sanofi-aventis
Bridgewater, NJ
USA

Y. Takei
Nagoya University
Nagoya
Japan

F. Torrens (Biography
F. Torrens

Dr. Torrens obtained a doctorate (Ph.D.) in Physical Chemistry from the Universitat de València, Spain. Currently Dr. Torrens is Lecturer in Physical Chemistry in the Universitat de València. His scientific accomplishments include the first implementation in a computer at the Universitat de València of a program for the elucidation of crystallographic structures and the construction of the first computational-chemistry program adapted to a vector-facility supercomputer in a Spanish university. He has published 2 books, 370 articles and 1672 presentations. He has been Advisor of 4 Ph.D. and 1 M.Sc.

)

University of Valencia
Valencia
Spain

J. Vaidyanathan
University of Medicine and Dentistry of NJ
Newark, NJ
USA

L.C. Wienkers
Amgen Inc
Seattle, WA
USA

S. Yamagishi (Biography
S. Yamagishi

Sho-ichi Yamagishi is a Professor and Chairman, Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Japan.

He has graduated from Kanazawa University School of Medicine, Japan and became a medical doctor in 1989. He has received a PhD from Kanazawa University, Japan in 1993. He received Basic Science Award "Angiogenesis Stem Cell Award" from American Heart Association in 2003 and "Distinguished Investigator Award from Japan Diabetes Society in 2005. He is serving as an editorial board member of 20 reputed journals and publishes more than 550 research papers, including Nature, JCI, and Diabetes, etc. His research fields are Diabetes, Cardiology and Gerontology.

)

Kurume University School of Medicine
Kurume
Japan

X.F.S. Zheng (Biography
X.F.S. Zheng

Dr. Zheng is University Professor and Chief, Division of Cancer Pharmacology, Rutgers University, and Co-leader, Cancer Pharmacology Program at the NCI-Designated Comprehensive Cancer Center Consortium of Rutgers and Princeton Universities. Dr. Zheng received his PhD degree and postdoctoral training at Harvard University. His long-standing research interest is mTOR signaling in growth and metabolism regulation, and the role in cancer biology and therapeutic targeting. He made major contributions to the mTOR field, including demonstration of TOR as the physiological target of rapamycin and elucidation of the mechanism of rapamycin action, and discovery of many key components and functions of TOR pathway.

)

UMDNJ-Robert Wood Johnson Medical School
Piscataway, NJ
USA












Advertisement

Related Journals




Related eBooks



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science